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Abstract
Obstructive sleep apnea (OSA) is a common medical condition that occurs in approximately
5% to 15% of the population. It is usually associated with an increased risk of cardiovascular
disease. Diagnosis of OSA is based on polysomnography, and its severity is measured with an
apnea-hypopnea index. Most of the adverse effects of OSA on the cardiovascular system are
reversible with treatment. In addition to continous positive airway pressure therapy, precau-
tions such as weight loss, avoidance of central nervous system depressants, treatment of nasal
congestion and sleeping in the lateral position may help to treat OSA. (Cardiol J 2007; 14: 534–537)
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Introduction
Obstructive sleep apnea (OSA) is a disorder,
characterised by repeated episodes of breath ces-
sation during sleep, which is usually seen together
with daytime sleepiness and/or altered cardiac func-
tion. It is usually associated with increased cardio-
vascular morbidity and mortality [1].
The main objectives of this paper is to summa-
rize the pathophysiological and clinical aspects of
OSA and to discuss its cardiovascular effects and
the treatment of this condition.
Definition and frequency
Sleep apnea is defined as a cessation of breath-
ing activity during sleep due to either dysfunction
of the central respiratory control mechanisms or
a mechanical collapse and obstruction of the upper
airways. The former is known as central sleep ap-
nea and the latter as OSA [2].
Obstructive sleep apnea is the more common
form of sleep apnea and occurs in approximately 5%
to 15% of the population [2, 3]. It is characterized
by hypopnea and apnea intervals leading to a 4% de-
crease in oxygen saturation usually in overweight
patients who suffer from daytime sleepiness [2].
During collapse periods the pharynx is partially or
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completely closed and sleep is fragmented, so pa-
tients suffer from daytime sleepiness [4]. The ap-
nea-hypopnea index (AHI), which is the number of
apneic and hypopneic events per hour, is used to de-
termine the severity of sleep apnea, defining apnea
as mild if AHI is between 5 and 15, moderate be-
tween 15 and 30 and severe if AHI is above 30. Car-
diovascular risk is increased in patients whose AHI
is over 30 per hour [5].
The effects of obstructive sleep apnea
on the cardiovascular system
Although known to be a benign disease, retro-
spective studies have shown that OSA is usually
associated with increased morbidity and mortality
due to systemic and/or pulmonary hypertension,
heart failure, myocardial infarction and stroke [1].
However, it is good to remember that most of the
adverse effects of OSA on the cardiovascular sys-
tem are reversible with treatment. Moreover, con-
tinuous positive airway pressure (CPAP) ventila-
tion therapy has been shown to have cardioprotec-
tive effects and to decrease mortality and morbidity
among those patients. Increased cardiovascular risk
in OSA is independent of confounding factors such
as obesity, hyperlipidemia or metabolic disease [6].
The effects of OSA on the cardiovascular sys-
tem can be divided into long- and short-term impli-
cations. Short-term effects are known to be related
to mechanical effects such as sudden intrathoracic
pressure changes, hypoxia, hypercapnia induced
chemical substance release, sympathetic-mediated
vasoconstriction, increased after-load, increased
left ventricular transmural pressure and arousal
from sleep. However, long-term effects are the re-
sults of some complex dysfunctions which are not
very well known. Autonomic dysfunction (mainly by
repetitive increase in sympathetic tone), malfunc-
tioning of the carotid body, production of free oxy-
gen radicals, decreased nitric oxide levels and en-
dothelial dysfunction, pro-inflammatory changes
(increased levels of cell adhesion molecules, inter-
leukin 6, tumour necrosis factor alpha and C-reac-
tive protein), tendency to coagulation by increased
thrombocyte aggregation, higher leptin levels and
enhanced atherosclerosis are potential mechanisms
for long term effects [4, 6, 7].
It has been shown that manoeuvres such as
induction of hypoxia can cause blood pressure
changes during sleep [8]. Systemic arterial hyper-
tension, with a prevalence of 50%, is the leading
cardiovascular abnormality that is related to OSA [9].
The association between OSA and hypertension is
independent of age, sex, previous blood pressure
history, body mass index and smoking [10, 11].
Hypoxia and hypercapnia induced sympathetic acti-
vation, increased endothelin and decreased nitric
oxide levels and hence endothelial dysfunction, in-
creased arterial stiffness and vascular resistance are
possible mechanisms behind this predisposition [12].
In a prospective follow up of 709 patients, Peppard
et al. [10] found that OSA was predictive of the pres-
ence of hypertension four years later.
Associated with OSA, pulmonary hypertension
is seen approximately 30%, coronary artery disease
20–30%, congestive heart failure 10%, and stroke
can be seen as much as 10%. Arrhythmias are the
other disorders which can be induced by OSA dur-
ing the sleep period [13].
Obstructive sleep apnea is an independent risk
factor for coronary artery disease. Increased C-re-
active protein and oxidative stress, hypoxia itself,
increased sympathetic activity, tachycardia, cardi-
ac oxygen demand increase, increased systemic
vascular resistance, increased tendency to throm-
bosis and many other unknown mechanisms cause
an increased risk for coronary events in OSA pa-
tients. Moreover, in a study by Tan et al. [14] in-
terestingly it was found that OSA has a negative
effect on the preventive functions of high-density
lipoprotein, which contributes to the effect of OSA
increasing the risk for coronary artery disease.
Obstructive sleep apnea associated heart fail-
ure has a prevalence of approximately 10% [11, 15].
Besides causing left ventricular systolic function
impairment through the well-known causes of heart
failure such as hypertension and coronary artery
disease, OSA can directly affect the ventricular
functions [11, 16, 17]. Increased sympathetic drive,
increased endothelin and endothelial dysfunction,
increased systemic vascular resistance, inflamma-
tory cytokines and transmural pressures are well-
known OSA induced mechanisms deteriorating ven-
tricular systolic and diastolic functions [4]. Tanriv-
erdi et al. [16] illustrated that OSA patients
exhibited a mild decrease in left ventricle systolic
function, which was not attributable to the well-
known causes of left ventricle dysfunction. They
concluded that aortic elasticity was also deteriorat-
ed and increased aortic stiffness might be respon-
sible for many of the cardiovascular alterations
caused by this disease. Likewise, a cross sectional
cohort study by Phillips et al. [18] concluded that
systemic arterial stiffness was positively correlat-
ed with the severity of OSA.
Obstructive sleep apnea is also associated with
an increased risk of stroke, independent of any
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other cardiovascular risk factors [19]. The factors that
may increase the risk of stroke in OSA include acute
reduction in cerebral blood flow due to apnea, hy-
poxemia and prothrombotic state and a tendency
towards atherosclerosis, and hypertension. Stroke
is an important cause of mortality and morbidity
among patients suffering from OSA [4, 11, 19, 20].
Obstructive sleep apnea is associated with
a broad range of arrhythmias such as atrial fibrilla-
tion (AF), sinoatrial or atrioventricular block, sinus
node dysfunction, bradyarrhythmia and asystole.
Rhythm disturbances such as bradycardia are
known as a typical feature of OSA [21]. Additional-
ly, a study by Harbison et al. [22] showed the pres-
ence of a relationship between rhythm disturbanc-
es and the severity of OSA.
Hypoxia and apnea induced vagal tone increase
trigger, especially nocturnal bradyarrhythmias.
Therefore, physicians have to evaluate carefully any
nocturnal dysrhythmia in terms of OSA coexistence
in order not to make an unnecessary pacemaker
implantation decision [4, 11]. Consequently, in such
a case, only CPAP therapy may successfully over-
come the arrhythmia [19]. The hypoxemia, sympa-
thetic overactivation, pressure surges, increased
cardiac wall stress and transmural pressures may
increase the likelihood of AF in OSA patients. Fur-
thermore, in patients who underwent cardioversion
for AF, if sleep apnea is accompanying, there is a two-
fold increase in the risk of recurrence of AF within
12 months compared with OSA patients treated with
CPAP. Accordingly, CPAP therapy in OSA patients
is shown to decrease AF recurrence [4, 23].
Reynolds et al. [24] showed that among OSA
patients, heart rate variability increased as apnea
severity increased. However, during REM sleep
there was a decrease in heart rate variability which
also suggested autonomic dysfunction in OSA pa-
tients. Yang et al. [25] found that there were chang-
es in heart rate turbulence of the OSA patients in
the absence of overt cardiac disease, which corre-
lates with the severity of OSA and are again related
to the abnormalities in cardiac autonomic activity.
Besides systemic hypertension, long lasting
OSA can cause pulmonary hypertension and right
ventricular failure without any underlying pulmo-
nary or cardiovascular disease [11].
Diagnosis and treatment
Patients possibly having OSA were identified
using the Epworth Sleepiness Scale (an eight-item
questionnaire assessing sleep quality and symptoms
related to OSA). The standard test for OSA diagno-
sis is polysomnography including electrocardiogra-
phy, oxygen saturation measurements, electroen-
cephalography, electro-oculography, snoring micro-
phone and assessment of body positions by video
recording with an infrared camera for the whole
night during the patient’s habitual sleep hours. Poly-
somnography shows an obvious drop in tidal volume
— a decrease in oxygen saturation during the ap-
nea and hypopnea episodes which are terminated by
an arousal detected by EEG [26].
Precautions such as weight loss, avoidance of
central nervous system depressants, treatment of
nasal congestion and sleeping in the lateral position
may help to treat OSA, as well as CPAP, the noninva-
sive treatment shown to normalize oxygen saturation,
improve regulation of systemic and pulmonary
hypertension, improve cognitive performance and
mood, decrease somnolence and improve daytime
alertness and quality of life and reduce mortality
[27–30]. CPAP treatment may also prevent noctur-
nal ST-segment depression, improve left ventricu-
lar systolic and diastolic functions, improve func-
tional class and decrease the risk of cardiac arrhyth-
mias in patients with heart failure [31]. In recent
years, a number of automatic CPAP systems in the
variable-pressure mode have been in use, which has
resulted in decreased overnight cumulative CPAP
levels, which seems to improve the efficacy and
tolerability of OSA treatment [32]. Other than non-
invasive treatment strategies, surgical procedures
to overcome the obstruction such as uvulopalat-
opharyngoplasty, laser uvulopalatoplasty, tonsillec-
tomy, partial resection or ablation of the tongue,
reconstruction of the mandible or maxille and tra-
cheostomy may be used for selected cases [24, 32].
Conclusions
Obstructive sleep apnea is a common, treata-
ble but underdiagnosed disease state, which should
be kept in mind by physicians dealing with cardio-
vascular disorders. Sleep quality has to be a part of
routine history taking in cardiovascular practice
because a broad spectrum of cardiovascular disor-
ders can be effectively prevented merely by treat-
ing OSA. Because of its systemic effects, many
other disease states such as pulmonary throm-
boembolism or even aortic aneurysm and dissec-
tion are areas for concern that should be studied
for a direct association with OSA [26, 33].
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